Dr. Moncef Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology. Dr. Slaoui was directly involved in GSK’s vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix, to prevent shingles; Cervarix, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease.
Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership, the operation enabled the fastest-ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company.
Dr. Slaoui received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium and has authored more than 100 scientific papers and presentations. A citizen of Morocco, Belgium and the USA, he is fluent in English, French and Arabic.
Dr. Slaoui also currently serves on the board of directors of Abzena and Cedar Health and is an Advisor to Kiniciti.
